Novo Holdings A S Sells 135,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Novo Holdings A S trimmed its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,250,000 shares of the company's stock after selling 135,000 shares during the period. Viridian Therapeutics comprises 2.6% of Novo Holdings A S's holdings, making the stock its 12th largest position. Novo Holdings A S owned approximately 2.84% of Viridian Therapeutics worth $43,132,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Viridian Therapeutics during the fourth quarter worth $26,000. Foresite Capital Management VI LLC purchased a new position in Viridian Therapeutics during the fourth quarter worth about $38,000. AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Viridian Therapeutics in the 4th quarter valued at approximately $164,000.

Viridian Therapeutics Stock Down 7.4 %

Shares of NASDAQ VRDN traded down $0.97 during trading on Tuesday, reaching $12.15. 565,472 shares of the stock were exchanged, compared to its average volume of 1,193,448. The business's 50-day moving average price is $13.92 and its 200 day moving average price is $17.77. The company has a market capitalization of $990.99 million, a price-to-earnings ratio of -2.83 and a beta of 0.57. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company's revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on VRDN. Needham & Company LLC reissued a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.